JP2016513069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513069A5 JP2016513069A5 JP2015540830A JP2015540830A JP2016513069A5 JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5 JP 2015540830 A JP2015540830 A JP 2015540830A JP 2015540830 A JP2015540830 A JP 2015540830A JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- aqueous
- dvd
- protein
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013011 aqueous formulation Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721364P | 2012-11-01 | 2012-11-01 | |
| US61/721,364 | 2012-11-01 | ||
| US201361794231P | 2013-03-15 | 2013-03-15 | |
| US61/794,231 | 2013-03-15 | ||
| PCT/US2013/068110 WO2014071212A2 (en) | 2012-11-01 | 2013-11-01 | Stable dual variable domain immunoglobulin protein formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019118152A Division JP2019189633A (ja) | 2012-11-01 | 2019-06-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513069A JP2016513069A (ja) | 2016-05-12 |
| JP2016513069A5 true JP2016513069A5 (Direct) | 2016-12-22 |
Family
ID=49585619
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540830A Pending JP2016513069A (ja) | 2012-11-01 | 2013-11-01 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
| JP2019118152A Pending JP2019189633A (ja) | 2012-11-01 | 2019-06-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
| JP2020178626A Pending JP2021020943A (ja) | 2012-11-01 | 2020-10-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019118152A Pending JP2019189633A (ja) | 2012-11-01 | 2019-06-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
| JP2020178626A Pending JP2021020943A (ja) | 2012-11-01 | 2020-10-26 | 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20140161817A1 (Direct) |
| EP (2) | EP3466973A1 (Direct) |
| JP (3) | JP2016513069A (Direct) |
| KR (1) | KR20150079866A (Direct) |
| CN (1) | CN105431453A (Direct) |
| AU (3) | AU2013337644A1 (Direct) |
| BR (1) | BR112015009924A2 (Direct) |
| CA (1) | CA2889488A1 (Direct) |
| HK (1) | HK1213204A1 (Direct) |
| IL (2) | IL238264A0 (Direct) |
| MX (2) | MX2015005495A (Direct) |
| RU (2) | RU2020139283A (Direct) |
| SG (2) | SG10201802044RA (Direct) |
| TW (3) | TW201422236A (Direct) |
| WO (1) | WO2014071212A2 (Direct) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010286518C1 (en) | 2009-08-29 | 2015-08-27 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
| EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
| NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| TW201811825A (zh) | 2012-11-01 | 2018-04-01 | 美商艾伯維有限公司 | 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途 |
| EP3077418A2 (en) | 2013-12-02 | 2016-10-12 | AbbVie Inc. | Compositions and methods for treating osteoarthritis |
| WO2015138337A1 (en) * | 2014-03-09 | 2015-09-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946765B1 (en) | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| US20160002326A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| US20160244520A1 (en) | 2015-01-24 | 2016-08-25 | Abbvie Inc. | Compositions and methods for treating psoriatic arthritis |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3349795B1 (en) * | 2015-09-17 | 2021-03-17 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| CA3010329A1 (en) * | 2015-12-29 | 2017-07-06 | Oncobiologics, Inc. | Buffered formulations of bevacizumab |
| NZ783685A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| CN108261391B (zh) | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
| CN108261544B (zh) | 2016-12-30 | 2023-05-05 | 江苏太平洋美诺克生物药业股份有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
| JP7407699B2 (ja) | 2017-07-28 | 2024-01-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体製剤 |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| US20210115156A1 (en) * | 2018-04-13 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fc-engineered anti-human ige antibodies and methods of use |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| CN110585430B (zh) * | 2019-09-29 | 2023-09-08 | 华博生物医药技术（上海）有限公司 | 一种人源化抗人il-17a单克隆抗体的药物组合物 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113082203B (zh) * | 2020-01-09 | 2023-10-20 | 鲁南制药集团股份有限公司 | 一种免疫抑制剂单克隆抗体的液体制剂 |
| WO2021215375A1 (ja) * | 2020-04-20 | 2021-10-28 | 塩野義製薬株式会社 | Ｈｍｇｂ１部分ペプチドを含有する製剤 |
| AU2021377176A1 (en) * | 2020-11-11 | 2023-06-22 | Hq Han | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
| WO2022113105A1 (en) * | 2020-11-25 | 2022-06-02 | Dr. Reddy's Laboratories Limited | Stable therapeutic protein formulation and methods of making the same |
| US20250332255A1 (en) * | 2024-04-30 | 2025-10-30 | Context Therapeutics Inc. | Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof |
| CN120346170A (zh) * | 2025-03-13 | 2025-07-22 | 武汉友芝友生物制药股份有限公司 | 抗EpCAM和CD3双特异性抗体药物组合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CZ333796A3 (cs) | 1991-03-06 | 1998-06-17 | MERCK Patent Gesellschaft mit beschränkter Haftung | Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| PL357448A1 (en) | 2000-02-25 | 2004-07-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| ES2259030T3 (es) | 2000-05-19 | 2006-09-16 | Scancell Limited | Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico. |
| CA2411374C (en) * | 2000-06-29 | 2012-10-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MX363905B (es) * | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2009241589B2 (en) * | 2008-04-29 | 2013-10-10 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP3002299A1 (en) * | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TW201012475A (en) * | 2008-07-08 | 2010-04-01 | Abbott Lab | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| TR201903279T4 (tr) * | 2010-03-25 | 2019-03-21 | Ucb Biopharma Sprl | Disülfür stabilize edilmiş DVD-IG molekülleri. |
| KR101539684B1 (ko) * | 2010-05-14 | 2015-07-27 | 애브비 인코포레이티드 | Ｉｌ－１ 결합 단백질 |
| UY33702A (es) * | 2010-11-02 | 2012-05-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2655417A2 (en) * | 2010-12-21 | 2013-10-30 | AbbVie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
-
2013
- 2013-11-01 CN CN201380057309.8A patent/CN105431453A/zh active Pending
- 2013-11-01 RU RU2020139283A patent/RU2020139283A/ru unknown
- 2013-11-01 TW TW102139863A patent/TW201422236A/zh unknown
- 2013-11-01 TW TW107111541A patent/TW201838651A/zh unknown
- 2013-11-01 BR BR112015009924A patent/BR112015009924A2/pt not_active Application Discontinuation
- 2013-11-01 HK HK16101327.4A patent/HK1213204A1/zh unknown
- 2013-11-01 TW TW108137919A patent/TW202033215A/zh unknown
- 2013-11-01 SG SG10201802044RA patent/SG10201802044RA/en unknown
- 2013-11-01 JP JP2015540830A patent/JP2016513069A/ja active Pending
- 2013-11-01 SG SG11201503324WA patent/SG11201503324WA/en unknown
- 2013-11-01 CA CA2889488A patent/CA2889488A1/en not_active Abandoned
- 2013-11-01 EP EP18171273.8A patent/EP3466973A1/en not_active Withdrawn
- 2013-11-01 EP EP13792165.6A patent/EP2914626A2/en not_active Ceased
- 2013-11-01 AU AU2013337644A patent/AU2013337644A1/en not_active Abandoned
- 2013-11-01 US US14/070,155 patent/US20140161817A1/en not_active Abandoned
- 2013-11-01 WO PCT/US2013/068110 patent/WO2014071212A2/en not_active Ceased
- 2013-11-01 MX MX2015005495A patent/MX2015005495A/es unknown
- 2013-11-01 KR KR1020157013990A patent/KR20150079866A/ko not_active Abandoned
- 2013-11-01 RU RU2015120605A patent/RU2015120605A/ru unknown
-
2015
- 2015-04-13 IL IL238264A patent/IL238264A0/en unknown
- 2015-04-29 MX MX2019003214A patent/MX2019003214A/es unknown
-
2016
- 2016-11-04 US US15/343,327 patent/US20170210796A1/en not_active Abandoned
-
2018
- 2018-10-24 AU AU2018253520A patent/AU2018253520A1/en not_active Abandoned
-
2019
- 2019-06-26 JP JP2019118152A patent/JP2019189633A/ja active Pending
-
2020
- 2020-01-17 US US16/745,579 patent/US20200385456A1/en not_active Abandoned
- 2020-08-12 IL IL276688A patent/IL276688A/en unknown
- 2020-09-30 AU AU2020244482A patent/AU2020244482A1/en not_active Abandoned
- 2020-10-26 JP JP2020178626A patent/JP2021020943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513069A5 (Direct) | ||
| HRP20192202T1 (hr) | Acc inhibitori i njihove upotrebe | |
| JP2016512050A5 (Direct) | ||
| JP2012045397A5 (Direct) | ||
| CL2014003370A1 (es) | Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición. | |
| EA201390081A1 (ru) | Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение | |
| PL3060229T3 (pl) | Stabilne, wodne formulacje przeciwciała | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| TWD168530S (zh) | 容器 | |
| UA115811C2 (uk) | Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування | |
| TWD167214S (zh) | 包裝用容器 | |
| TWD167749S (zh) | 電連接器 | |
| JP2015525307A5 (Direct) | ||
| JP2015516943A5 (Direct) | ||
| JP2013535391A5 (Direct) | ||
| JP2013227283A5 (Direct) | ||
| CY1123536T1 (el) | Τρυγικο αλας του 5-χλωρο-θειοφαινο-2-καρβοξυλικου οξεος [(s)-2-[meθyλo-3-(2-oξo-πυρρολιδιν-1-υλ)-βενζολοσουλφονυλαμινο]-3-(4-μεθυλο-πιπεραζιν-1-υλ)-3-οξο-προπυλ]αμιδιου | |
| JP2012186616A5 (Direct) | ||
| JP2016107746A5 (Direct) | ||
| JP2014159381A5 (Direct) | ||
| TWD162138S (zh) | 眼鏡（二） | |
| CN302314208S (zh) | 眼镜（tw13） | |
| CN302314221S (zh) | 眼镜（026） | |
| CN302314225S (zh) | 眼镜（tw14） | |
| TWD175622S (zh) | 可摺疊髮梳 |